Wall Street Zen Downgrades bioAffinity Technologies (NASDAQ:BIAF) to Strong Sell

bioAffinity Technologies (NASDAQ:BIAF) was downgraded by investment analysts at Wall Street Zen to a “strong sell” rating in a report released on Saturday.

bioAffinity Technologies Price Performance

bioAffinity Technologies stock opened at $4.98 on Friday. The company has a debt-to-equity ratio of 0.27, a current ratio of 0.64 and a quick ratio of 0.63. The company has a market capitalization of $147.26 million, a PE ratio of -7.11 and a beta of 2.52. bioAffinity Technologies has a one year low of $4.02 and a one year high of $67.78. The business has a 50 day simple moving average of $8.29 and a 200 day simple moving average of $10.03.

bioAffinity Technologies (NASDAQ:BIAF) last posted its earnings results on Thursday, August 14th. The company reported ($3.90) EPS for the quarter, missing the consensus estimate of ($3.00) by ($0.90). The company had revenue of $1.27 million for the quarter, compared to the consensus estimate of $1.51 million. bioAffinity Technologies had a negative return on equity of 845.68% and a negative net margin of 152.16%.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.